Literature DB >> 12743223

Clinical spectrum of succinic semialdehyde dehydrogenase deficiency.

P L Pearl1, K M Gibson, M T Acosta, L G Vezina, W H Theodore, M A Rogawski, E J Novotny, A Gropman, J A Conry, G T Berry, M Tuchman.   

Abstract

Succinic semialdehyde dehydrogenase (SSADH) deficiency is a rare autosomal recessive disorder affecting CNS gamma-aminobutyric acid (GABA) degradation. SSADH, in conjunction with GABA transaminase, converts GABA to succinate. In the absence of SSADH, GABA is converted to 4-OH-butyrate. The presence of 4-OH-butyrate, a highly volatile compound, may be undetected on routine organic acid analysis. Urine organic acid testing was modified at the authors' institution in 1999 to screen for the excretion of 4-OH-butyrate by selective ion monitoring gas chromatography-mass spectrometry in addition to total ion chromatography. Since then, five patients with 4-hydroxybutyric aciduria have been identified. The authors add the clinical, neuroimaging, and EEG findings from a new cohort of patients to 51 patients reported in the literature with clinical details. Ages ranged from 1 to 21 years at diagnosis. Clinical findings include mild-moderate mental retardation, disproportionate language dysfunction, hypotonia, hyporeflexia, autistic behaviors, seizures, and hallucinations. Brain MRI performed in five patients at the authors' institution revealed symmetric increased T2 signal in the globus pallidi. SSADH deficiency is an under-recognized, potentially manageable neurometabolic disorder. Urine organic acid analysis should include a sensitive method for the detection of 4-hydroxybutyrate and should be obtained from patients with mental retardation or neuropsychiatric disturbance of unknown etiology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12743223     DOI: 10.1212/01.wnl.0000059549.70717.80

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  54 in total

Review 1.  Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance.

Authors:  Kyung-Jin Kim; Phillip L Pearl; Kimmo Jensen; O Carter Snead; Patrizia Malaspina; Cornelis Jakobs; K Michael Gibson
Journal:  Antioxid Redox Signal       Date:  2011-04-10       Impact factor: 8.401

2.  ConceptMetab: exploring relationships among metabolite sets to identify links among biomedical concepts.

Authors:  Raymond G Cavalcante; Snehal Patil; Terry E Weymouth; Kestutis G Bendinskas; Alla Karnovsky; Maureen A Sartor
Journal:  Bioinformatics       Date:  2016-01-21       Impact factor: 6.937

3.  Therapeutic efficacy of magnesium valproate in succinic semialdehyde dehydrogenase deficiency.

Authors:  Elena Vanadia; K Michael Gibson; Phillip L Pearl; Emanuele Trapolino; Salvatore Mangano; Francesca Vanadia
Journal:  JIMD Rep       Date:  2012-08-22

Review 4.  Current concepts in organic acidurias: understanding intra- and extracerebral disease manifestation.

Authors:  Stefan Kölker; Peter Burgard; Sven W Sauer; Jürgen G Okun
Journal:  J Inherit Metab Dis       Date:  2013-03-20       Impact factor: 4.982

5.  Cerebellar atrophy in human and murine succinic semialdehyde dehydrogenase deficiency.

Authors:  Maria T Acosta; Jeeva Munasinghe; Phillip L Pearl; Maneesh Gupta; Andrey Finegersh; K Michael Gibson; William H Theodore
Journal:  J Child Neurol       Date:  2010-05-05       Impact factor: 1.987

Review 6.  Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men.

Authors:  P L Pearl; K M Gibson; M A Cortez; Y Wu; O Carter Snead; I Knerr; K Forester; J M Pettiford; C Jakobs; W H Theodore
Journal:  J Inherit Metab Dis       Date:  2009-01-28       Impact factor: 4.982

Review 7.  Seizures and metabolic disease.

Authors:  Phillip L Pearl; Heather D Bennett; Zarir Khademian
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

8.  Taurine trial in succinic semialdehyde dehydrogenase deficiency and elevated CNS GABA.

Authors:  Phillip L Pearl; John Schreiber; William H Theodore; Robert McCarter; Emily S Barrios; Joe Yu; Edythe Wiggs; Jianping He; K Michael Gibson
Journal:  Neurology       Date:  2014-02-12       Impact factor: 9.910

9.  Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies.

Authors:  Mahsa Parviz; Kara Vogel; K Michael Gibson; Phillip L Pearl
Journal:  J Pediatr Epilepsy       Date:  2014-11-25

Review 10.  Comparative genomics of aldehyde dehydrogenase 5a1 (succinate semialdehyde dehydrogenase) and accumulation of gamma-hydroxybutyrate associated with its deficiency.

Authors:  Patrizia Malaspina; Matthew J Picklo; C Jakobs; O Carter Snead; K Michael Gibson
Journal:  Hum Genomics       Date:  2009-01       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.